Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial
about
Treatment of Elderly Patients with Squamous Cell Carcinoma of the Head and NeckTreatment of head and neck cancer in the elderly.Appropriate Sequence for Afatinib and Cisplatin Combination Improves Anticancer Activity in Head and Neck Squamous Cell CarcinomaSystemic Drug-induced Chronic Paronychia and Periungual Pyogenic Granuloma
P2860
Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 April 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Afatinib versus methotrexate i ...... of the LUX-Head & Neck 1 trial
@en
Afatinib versus methotrexate i ...... f the LUX-Head & Neck 1 trial.
@nl
type
label
Afatinib versus methotrexate i ...... of the LUX-Head & Neck 1 trial
@en
Afatinib versus methotrexate i ...... f the LUX-Head & Neck 1 trial.
@nl
prefLabel
Afatinib versus methotrexate i ...... of the LUX-Head & Neck 1 trial
@en
Afatinib versus methotrexate i ...... f the LUX-Head & Neck 1 trial.
@nl
P2093
P2860
P356
P1433
P1476
Afatinib versus methotrexate i ...... of the LUX-Head & Neck 1 trial
@en
P2093
D Cupissol
E E W Cohen
E Ehrnrooth
F Caponigro
J B Vermorken
J M Del Campo
J P Machiels
P2860
P304
P356
10.1093/ANNONC/MDW151
P577
2016-04-15T00:00:00Z